Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-147 in APOL1-mediated FSGS
NCT04340362Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of inaxaplin in focal segmental glomerulosclerosis (FSGS), sponsored by Vertex Pharmaceuticals. Started Jun 2020; status: completed.
02
Drugs
inaxaplin
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT04340362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340362.